Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvingtrans Regulatory News (AVG)

Share Price Information for Avingtrans (AVG)

Share Price is delayed by 15 minutes
Get Live Data
652.00    12.00 (1.88%)
Bid:
644.00
Ask:
660.00
Spread: 16.00 (2.484%)
Market Cap: £219.22m
AVG Live PriceLast checked at - London Stock Exchange

Intraday Avingtrans Share Chart

Divisional Board Appointment

30 Jul 2014 07:00

RNS Number : 6675N
Avingtrans PLC
30 July 2014
Ā 



Ā 

Ā 

30 July 2014

RNS REACH

Ā 

Avingtrans Plc

("Avingtrans" or the "Company" or the "Group")

Ā 

Divisional Board Appointment

Avingtrans plc (AIM: AVG), a manufacturer of critical components and associated services to the global aerospace, energy and medical sectors, has appointed Dr Gareth Job as a Divisional Non-Executive Director for Energy and Medical. He will join the divisional board with effect from 1 August 2014.

Dr Job has 25 years' experience within the Oil & Gas industry and is currently employed full time in a senior project director role with Technip, a world leading energy industry engineering group. Prior to this Gareth helped pioneer best practice within the International Engineering and Construction Industry in Risk Management as head of Project Risk Management for Shaw Energy and Chemicals and as a Director of the Engineering and Construction Risk Institute (ECRI). Gareth has a PhD in Chemical Engineering, is a Chartered Engineer and he has particular interest in offshore and onshore oil and gas projects. His specialities include project management, commercial management and risk analysis.

Commenting on the appointment, Steve McQuillan, CEO of Avingtrans said: "Gareth is a very talented individual with many years of experience in the Oil & Gas industry. His appointment will strengthen our Division, as Avingtrans continues to increase its presence and influence in oil and gas and energy markets in general."

Dr Gareth Job commented: "I am delighted to be joining the Energy and Medical Divisional Board at Avingtrans. The Company has a strong product offering, which it is rebuilding as it integrates Maloney Metalcraft with the rest of the division and is well placed to grow significantly in the oil and gas arena."

Ā 

For further information, please contact:

Ā 

Enquiries:

Avingtrans plc 0115 949 9020

Steve McQuillan, CEO

Stephen King, CFOĀ 

Ā 

Numis

David Poutney (Corporate Broking) 0207 260 1000

Richard Thomas (Corporate Finance and Nominated Adviser)

Newgate Threadneedle 020 7653 9850

(Financial PR)

Josh Royston / Heather Armstrong

Ā 

About Avingtrans

Ā 

Avingtrans plc is engaged in the provision of highly engineered components, modules and services to the Aerospace, Energy and Medical markets worldwide.

The business is made up of 2 divisions:

•

Aerospace, engaged in the manufacture of rigid pipe assemblies, fabrications and prismatic components - both metallic and composite - for the global aerospace market and precision polishing of aircraft components and;

Ā 

•

Energy and medical, engaged in the design and manufacture of machined and fabricated pressure and vacuum vessels and process plant and equipment for the power, oil & gas and medical markets. Plus, design and manufacture of fabricated poles and cabinets for roadside safety cameras and rail track signalling.

Ā 

Ā 

Ā 

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
NRAQKCDQABKDFOB
Date   Source Headline
19th May 202610:20 amRNSHolding(s) in Company
14th May 202612:26 pmRNSHolding(s) in Company
12th May 20267:00 amRNSAdaptix receives CE Certification
6th May 20264:28 pmRNSHolding(s) in Company
30th Apr 20262:42 pmRNSHolding(s) in Company
30th Apr 20262:41 pmRNSExercise of Options & TVR
24th Apr 20262:54 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSStrong Nuclear Orders for Avingtrans
26th Mar 20267:00 amRNS-RScientific Magnetics Ships 20th Quantum Magnet
4th Mar 20267:00 amRNSHolding(s) in Company
25th Feb 20267:00 amRNSInterim Results
12th Feb 202611:49 amRNSHolding(s) in Company
6th Feb 202610:24 amRNSHolding(s) in Company
27th Jan 20265:42 pmRNSExercise of Options & TVR
21st Jan 20267:00 amRNSTrading Update and Notice of Results
12th Jan 20265:13 pmRNSIssue of Share Options
12th Jan 20267:00 amRNS-RMedical & Industrial Imaging Division Appointment
8th Dec 20252:34 pmRNSNotification of Major Holdings
27th Nov 20251:59 pmRNSResult of AGM - Board Appointment
14th Nov 20258:38 amRNSExercise of Options & PDMR Dealings
10th Nov 20257:00 amRNSAdaptix receives FDA 510(K) clearance
1st Oct 20254:52 pmRNSExercise of Options & Total Voting Rights
1st Oct 20253:32 pmRNSHolding(s) in Company
29th Sep 20257:00 amRNSAppointment of Medical Division CEO
24th Sep 20257:00 amRNSPreliminary results for the year ended 31 May 2025
11th Sep 20258:00 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSHayward Tyler Secures $16m Nuclear Contracts
28th Aug 20257:00 amRNSBooth Industries secures £8.5m HS2 & TfL contracts
25th Jun 20257:00 amRNSTrading Update and Notice of Results
28th May 20257:00 amRNSTrading Update
26th Feb 20257:00 amRNSInterim Results
13th Feb 20257:00 amRNSBooth Industries secures £4.5m Contract
16th Jan 20257:00 amRNSTrading Update & Notice of Results
21st Nov 20244:09 pmRNSResult of AGM
24th Oct 20249:07 amRNSHolding(s) in Company
25th Sep 20247:00 amRNSPreliminary results for the year ended 31 May 2024
3rd Jul 20247:00 amRNSPDMR Dealings
19th Jun 20247:00 amRNSTrading Update and Notice of Results
26th Mar 202411:15 amRNSPDMR Dealings
21st Mar 20245:15 pmRNSExercise of Options, PDMR Dealings & TVR
20th Mar 20243:39 pmRNSHolding(s) in Company
4th Mar 20246:10 pmRNSPDMR Dealings
28th Feb 20247:00 amRNSInterim Results
18th Jan 20247:00 amRNSTrading Update and Notice of Results
15th Dec 20233:00 pmRNSExercise of Options & TVR
4th Dec 20237:00 amRNSMagnetica Limited appoints US distributor
22nd Nov 20237:00 amRNSEmployee & PDMR Share Incentive Awards
16th Nov 20232:20 pmRNSResult of AGM
13th Nov 20237:00 amRNSHayward Tyler Contract Win
11th Oct 20237:00 amRNSContract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.